Cost-Effectiveness Analysis of a Quadrivalent Human Papilloma Virus Vaccine in Mexico

Archives of Medical Research

Volumn 40, Issue 6, 2009, Pages 503-513

  Reynales Shigematsu, Luz Myriam ^a   Rodrigues, Eliane R ^b   Lazcano Ponce, Eduardo ^a  

^a INSTITUTO NACIONAL DE SALUD PÚBLICA   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

Cervical cancer; Cost effectiveness analysis; Quadrivalent HPV vaccine (HPV 6 11 16 18); Screening program

Indexed keywords

WART VIRUS VACCINE;

CANCER PREVENTION; CANCER RISK; CHEMOPROPHYLAXIS; COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; CYTOLOGY; DISEASE COURSE; EPIDEMIOLOGICAL DATA; HEALTH CARE POLICY; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; MEXICO; PAPANICOLAOU TEST; PERSISTENT VIRUS INFECTION; PROBABILITY; PUBLIC HEALTH; REVIEW; RISK REDUCTION; SCREENING; SECONDARY PREVENTION; STATISTICAL MODEL; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VACCINATION; VIRUS INFECTION;

COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMANS; INCIDENCE; MARKOV CHAINS; MEXICO; MODELS, ECONOMETRIC; MODELS, STATISTICAL; PAPILLOMAVIRUS VACCINES; QUALITY-ADJUSTED LIFE YEARS; VAGINAL SMEARS;

EID: 70350047087     PISSN: 01884409     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arcmed.2009.08.004     Document Type: Review

References (40)

1. PAHO.WHO 2001. Cancer Prevention. A Brief Snapshot of the Situation: Cervical Cancer in Latin America and the Caribbean, 2001. http://www.paho.org/English/HCP/HCN/CCBriefSnapshot.htm (accessed June 2008).
2. OPS. 2002. Cáncer del cuello del útero: creciente amenaza en las Américas. http://www.paho.org/Spanish/DPI/100/100feature06.htm (accessed June 2008).
3. Lazcano-Ponce E., Palacio-Mejia L.S., Allen-Leigh B., et al. Decreasing cervical cancer mortality in Mexico: effect of Papanicolaou coverage, birthrate, and the importance of diagnostic validity of cytology. Cancer Epidemiol Biomarkers Prev 17 (2008) 2808-2817
4. Palacio-Mejía L.S., Lazcano-Ponce E., Allen-Leigh B., et al. Regional differences in breast and cervical cancer mortality in Mexico between 1979-2006. Salud Publica Mex 51 suppl 2 (2009) S208-S219
5. SSA. Programa de Acción: Cáncer Cérvico-Uterino. Primera Edición; 2002.
6. Munoz N., Castellsagué X., Berrington de González B., et al. Chapter 1: HPV in the etiology of human cancer. Vaccine (2006) 24S3:S3/1-S3/10
7. Hernández-Ávila M., Lazcano-Ponce E.C., Berumen-Campos J., et al. Human papilloma virus 16-18 infection and cervical cancer in Mexico: a case-control study. Arch Med Res 28 (1997) 265-271
8. Lazcano-Ponce E., Rojas-Martínez R., López-Acuña M.P., et al. Factores de riesgo reproductivo y cáncer cervico-uterino en la Ciudad de México. Salud Pública Mex 35 (1993) 65-73
9. Harro C.D., and PangYY R.R. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst 93 (2001) 284-292
10. Schiller J., and Lowy D. Papillomavirus-like particle vaccines. J Natl Cancer Inst Monogr 93 28 (2001) 50
11. Koustky L.A., Aula K.A., Wheeler C.M., et al. A trial of a human papillomavirus type 16 vaccine. N Engl J Med 347 (2002) 1645-1651
12. Villa L.L., Costa R.L., Petta C.A., et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 6 (2005) 271-278
13. Franco E.L., Cuzick J., Hildesheim A., et al. Chapter 20: Issues in planning cervical cancer screening in the era of HPV vaccination. Vaccine (2006) 24S3:S3/171-S3/177
14. Goldie S.J., Goldhaber-Fiebert J.D., and Garnett G.P. Chapter 18: Public health policy for cervical cancer prevention: the role of decision science, economic evaluation, and mathematical modeling. Vaccine (2006) 24S3:S3/155-S3/163
15. Kulasingam S.L., and Myers E.R. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA 290 (2003) 781-798
16. Clifford G.M., Smith J.S., Aguado T., et al. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer 89 (2003) 101-105
17. Clifford G., Franceschi S., Diaz M., et al. Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine (2006) 24S3:S3/26-S3/34
18. Lacey C.J., Lowndes C.M., and Shah K. Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine (2006) 24S3:S3/35-S3/41
19. Norma Oficial Mexicana NOM-014-SSA2-1994 para la prevención, detección, diagnóstico, tratamiento, control y vigilancia epidemiológica del cáncer cérvico uterino; 1994.
20. Drummond M., O'Brien B., Stoddart G., et al. Métodos para la Evaluación Económica de los Programas de Asistencia Sanitaria. Segunda Edición (2001), Ediciones Díaz de Santos, Madrid
21. Evans D.B., Edejer T.T., Adam T., et al. Methods to assess the costs and health effects of interventions for improving health in developing countries. BMJ 331 7525 (2005) 1137-1140
22. WHO. Making choices in health. In: Tan-Torres Edejer T., Baltussen R., Adam T., Hutubessy R., Acharya A., Evans DB., and Murray CJL. (Eds). WHO guide to cost-effectiveness analysis (2003), WHO, Geneva
23. Muenning P. Designing and Conducting Cost-effectiveness Analyses in Medicine and Health Care (2002), John Wiley & Sons, San Francisco
24. Burchell N.A., Winer R.L., de Sanjosé S., et al. Chapter 6: Epidemiology and transmission dynamics of genital HPV infection. Vaccine (2006) 24S3:S3/52-S3/61
25. Banco de Mexico. GDP Per cápita Mexico 2004.
26. WHO (World Health Organization): WHO-CHOICE: World Health Organization statistical information system: CHOICE (CHOosing Interventions that are Cost Effective), April 21, 2006. www.who.int/whosis/en/. Disease Control Priorities Project.
27. Vaccarella S., Franceschi S., Herrero R., et al. IARC HPV Prevalence Surveys Study Group. Sexual behavior, condom use, and human papillomavirus: pooled analysis of the IARC human papillomavirus prevalence surveys. Cancer Epidemiol Biomarkers Prev 15 (2006) 326-333
28. Parkin D.M., Bray F., Ferlay J., et al. Global cancer statistics, 2002. CA Cancer J Clin 55 (2005) 74-108
29. Goldie S.J., Grima D., Kohli M., et al. A comprehensive natural history model of human papillomavirus (HPV) infection and cervical cancer: potential impact of an HPV 16/18 vaccine. Int J Cancer 106 (2003) 896-904
30. Franco E.L., Tsu V., Herrero R., et al. Integration of human papillomavirus vaccination and cervical cancer screening in Latin America and the Caribbean. Vaccine 26 suppl 11 (2008) L88-L95
31. DeWilde S., and Anderson R. Med Decis Making 24 (2004) 486-492
32. Garnett G.P., Kim J.J., French K., et al. Chapter 21: Modelling the impact of HPV vaccines on cervical cancer and screening programmes. Vaccine (2006) 24S3: S3/178-S3/186
33. Insinga R.P., Dasbach E.J., Elbasha E.H., et al. Cost-effectiveness of quadrivalent human papillomavirus (HPV) vaccination in Mexico: a transmission dynamic model-based evaluation. Vaccine 26 (2007) 128-139
34. Barnabas R.V., Laukkanen P., Koskela P., et al. Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses. PLoS Med 3 (2006) e138
35. Goldie S.J., Kohli M., Grima D., et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst 96 (2004) 604-615
36. Avila L., Cahuana L., and Pérez R. Cuentas nacionales de salud reproductive y equidad de genero (2005), Secretaría de Salud/Instituto Nacional de Salud Pública, Ciudad de Mexico/Cuernavaca, México
37. Myers E. Mathematical models as research tools for HPV disease. Papillomavirus Rep 13 (2002) 141-144
38. Lazcano-Ponce E., Herrero R., Munoz N., et al. Epidemiology of HPV infection among Mexican women with normal cervical cytology. Int J Cancer 91 (2001) 412
39. Lajous M., Mueller N., Cruz-Valdez A., et al. Determinants of prevalence, acquisition, and persistence of human papillomavirus in healthy Mexican military men. Cancer Epidemiol Biomarkers Prev 14 (2005) 1710-1716
40. Dasbach E.J., Elbasha E.H., and Insinga R.P. Mathematical models for predicting the epidemiologic and economics impact of vaccination against human papillomavirus infection and disease. Epidemiol Rev 28 (2006) 88-100